FranceTuberculosis profile
Population  2017 65 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.35 (0.33–0.38) 0.55 (0.51–0.58)
Mortality (HIV+TB only) 0.14 (0.072–0.22) 0.21 (0.11–0.34)
Incidence  (includes HIV+TB) 5.2 (4.5–5.8) 8 (7–9)
Incidence (HIV+TB only) 0.74 (0.44–1.1) 1.1 (0.67–1.7)
Incidence (MDR/RR-TB)** 0.094 (0.066–0.13) 0.14 (0.1–0.2)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.21 (0.2–0.21) 1.5 (1.4–1.6) 1.7 (1.6–1.9)
Males 0.27 (0.26–0.28) 3.2 (2.9–3.5) 3.4 (3.1–3.8)
Total 0.48 (0.46–0.5) 4.7 (4.1–5.2) 5.2 (4.5–5.8)
TB case notifications, 2017  
Total cases notified 5 131
Total new and relapse 4 839
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status  
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 94% (83–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.1 (0.08–0.12)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  65
(48–82)
Estimated % of TB cases with MDR/RR-TB 1% (0.65–1.5) 10% (7.1–15)  
% notified tested for rifampicin resistance 74% 98% 4 221
MDR/RR-TB cases tested for resistance to second-line drugs   79
Laboratory-confirmed cases MDR/RR-TB: 79, XDR-TB: 10
Patients started on treatment **** MDR/RR-TB: 79, XDR-TB: 10
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 54% 4 623
Previously treated cases, excluding relapse, registered in 2016 51% 284
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015    
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-12-16 Data: www.who.int/tb/data